Based on Ajinomoto Group’s collaborative development with Forge Biologics, now available worldwide Incheon, Korea — December 2025 — Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group ...
The company received FDA clearance to launch a Phase I trial of its therapy, which it says can overcome safety and efficacy concerns related to systemic AAV delivery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results